Precision BioSciences says PBGENE-HBV achieved undetectable viral RNA in 100% of evaluable hepatitis B patients in Phase 1

Precision BioSciences says PBGENE-HBV achieved undetectable viral RNA in 100% of evaluable hepatitis B patients at 0.4 mg/kg in Phase 1, and plans Phase 2 dosing in Q1 2027.

Detected & updated continuously · Source: Nebula